Burden of illness among patients at high risk versus low risk for major cardiovascular events

Abstract

Objective:

This study was designed to compare the burden of illness (BOI) in patients at high risk versus low risk of developing a major cardiovascular (CV) event.

Methods:

This retrospective claims data analysis included commercial health plan members identified with a primary diagnosis on a medical claim for cardiovascular disease (CVD) from January 1, 2001 through December 31, 2002. Patients were categorized as: low risk (LR), high risk (HR), or high risk aged ≥55 (HR55), based on the ONTARGET clinical trial.

Results:

Most patients (85%) were in the LR category (8% in HR55, 7% in HR). A significantly greater proportion of patients in the HR55 group were hospitalized and experienced a greater number of ambulatory visits compared with LR and HR patients. Controlling for covariates, HR55 patients averaged $22,502 in paid healthcare services over 2 years versus $15,645 for HR patients and $11,423 for LR patients (p < 0.001). CV-related costs represented about 46% of costs for the HR55 group, versus 41% for the HR group and 31% for the LR group.

Limitations:

Claims data are collected for the purpose of payment and not research and the presence of a diagnosis code is not proof of disease, due to possible coding errors or the use of a rule-out criterion. Also, patients who died in the follow-up were not included in the analyses, resulting in lower BOI estimates. Finally, the results of this study reflect treatment of CVD in managed-care settings, and may not be applicable to a different type of population.

Conclusion:

This study demonstrates the high BOI associated with CVD, especially for patients within the high-risk group aged ≥55 years. Opportunities exist for reducing costs in this population.

Key words:

• burden of illness
• cardiovascular disease
• claims analysis
• cost
• risk

Transparency

Declaration of funding:

This study was funded by Boehringer Ingelheim Pharmaceuticals, Inc.

Declaration of financial/other relationships:

C.H., V.Z., and F.C. have disclosed that they are employees of i3 Innovus, a company that received financial support from Boehringer Ingelheim Pharmaceuticals to conduct this study. S.D.S. and H.S. have disclosed that they are employees of Boehringer Ingelheim Pharmaceuticals, Inc.